Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence

Blood

Volumn 112, Issue 8, 2008, Pages 3026-3035

  Lataillade, Jean Jacques ^a   Pierre Louis, Olivier ^b,c   Hasselbalch, Hans Carl ^d   Uzan, Georges ^b,c   Jasmin, Claude ^b,c   Martyré, Marie Claire ^b,c   Le Bousse Kerdilès, Marie Caroline ^b,c  

^a PERCY MILITARY HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

CELL CLONE; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; DISEASE ASSOCIATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MYELOID METAPLASIA; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; BONE MARROW; CELL COMMUNICATION; CELL MOTION; GENETICS; HEMATOPOIETIC SYSTEM; METABOLISM; MOUSE; MYELOFIBROSIS; PHYSIOLOGY;

ANIMALS; BONE MARROW; CELL COMMUNICATION; CELL MOVEMENT; CELL PROLIFERATION; HEMATOPOIETIC STEM CELLS; HEMATOPOIETIC SYSTEM; HUMANS; JANUS KINASE 2; MICE; MODELS, BIOLOGICAL; MYELOFIBROSIS; SIGNAL TRANSDUCTION;

EID: 54049138867     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-158386     Document Type: Review

References (108)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:8520-8530.
3. Martyré MC, Le Bousse-Kerdiles MC. Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement. Semin Oncol. 2005; 32:373-379.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005:352:1779-1790.
7. Levine RL, Wadleigh M, Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
8. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med [http://medicine.plosjournals.org]. 2006;3(7):e270.
9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
10. Beer PA, Campbell PJ, Scott LM et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141-149.
11. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112:844-847.
12. Walz C, Crowley BJ, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006;281: 18177-18183.
13. Chaligné R, James C, Tonetti C, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007; 110:3735-3743.
14. Chaligné R, Tonetti C, Besancenot R, etal. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G(1)/S-phase transition. Leukemia. 2008;22:1557-1566.
15. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 2007;129:1097-1110.
16. Walkley CR, Shea JM, Sims NA, et al. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007;129:1081-1095.
17. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414:98-104.
18. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4:7-25.
19. Jasmin C, Poupon MF, Smadja-Joffe F, et al. Tumor stem cells and their ecosystem: therapeutic implications of a new concept. In: Macher E, Borg C, eds. R and B Symposium, Local Immunity in Cancer. Munich, Germany, Regensberg & Biersen; 1986:114-123.
20. Heissig B, Ohki Y, Sato Y, Rafii S. Werb Z, Hattori K. A role for niches in hematopoietic cell development. Hematology. 2005;10:247-253.
21. Suda T, Arai F, Hirao A. Hematopoietic stem cells and their niche. Trends Immunol. 2005;26:426-433.
22. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836-841.
23. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841-846.
24. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood. 2008; 111: 3923-3930.
25. Wilson A, Oser GM, Jaworski M, et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci. 2007;1106:64-75.
26. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda). 2005;20:349-356.
27. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121.
28. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol. 2008;8:290-301.
29. Fleming HE, Janzen V, Lo Celso C, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008;2:274-283.
30. Scadden DT. The stem cell niche in health and leukemic disease. Best Pract Res Clin Haematol. 2007;20:19-27.
31. Arai F, Suda T. Regulation of hematopoietic stem cells in the osteoblastic niche. Adv Exp Med Biol. 2007;602:61-67.
32. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008; 22:941-950.
33. Giebel B, Bruns I. Self-renewal versus differentiation in hematopoietic stem and progenitor cells: a focus on asymmetric cell divisions. Curr Stem Cell Res Ther. 2008;3:9-16.
34. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233-242.
35. Bilhou-Nabéra C, Brigaudeau C, Clay D, et al. Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis? Blood. 2003;102:1551-1552.
36. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981-1983.
37. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109:71-77.
38. Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65:104-108.
39. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125-139.
40. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88:4534-4546.
41. Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytc proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2005;105:464-473.
42. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
43. Andréasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 2002;68: 189-193.
44. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000;85:1126-1134.
45. Martyré MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9-16.
46. Zauli G. Visani G, Catani L. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrornbocythaemia. Br J Haematol. 1993;83:14-20.
47. Martyré MC, Le Bousse-Kerdilès MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97:441-448.
48. Castro-Malaspina H, Rabellino EM, Yen A, et al. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981;57:781-787.
49. Le Bousse-Kerdilès MC, Martyré MC. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris). 2001;49:153-157.
50. Le Bousse-Kerdilès MC, Martyré MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol. 1999;78: 437-444.
51. Le Bousse-Kerdilès MC, Martyré MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia: French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol. 1999;21:491-508.
52. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
53. Steurer M, Zoller H, Augustin F, et al. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol. 2007;38:1057-1064.
54. Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15:976-980.
55. Bock O, Loch G, Schade U, et al. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. Br J Haematol. 2005;130:76-82.
56. Wang JC, Hemavathy K, Charles W, et al. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). Exp Hematol. 2004;32:905-910.
57. Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood. 2003;101:2983-2989.
58. Yoder MC. Embryonic hematopoiesis in mice and humans. Acta Paediatr Suppl. 2002;91:5-8.
59. Briard D, Brouty-Boyé D, Giron-Michel J, et al. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol. 2003;106:201-212.
60. Brouty-Boyé D, Briard D, Azzarone B, Jasmin C, Le Bousse-Kerdilès MC. Effects of human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues on CD34+ stem cells. Int J Cancer. 2001;92:484-488.
61. Briard D, Brouty-Boyé D, Azzarone B, et al. Fibroblasts from human spleen regulate NK cell differentiation from blood CD34(+) progenitors via cell surface IL-15. J Immunol. 2002;168:4326-4332.
62. Brouty-Boyé D, Doucet C, Clay D, et al. Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues. Int J Cancer. 1998;76:767-773.
63. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10: 64-71.
64. Thiele J, Kvasnicka HM, Werden C, et al. Idiopathic primary osteo-myelofibrosis: a clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma. 1996;22:303-317.
65. Kees M, Wiesbauer F, Gisslinger B, et al. Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. Thromb Haemost. 2005;93:70-75.
66. Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124:618-625.
67. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:5688-5695.
68. + cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007; 38:280-286.
69. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells. 2007;25:165-173.
70. + cells from patients with primary myelofibrosis. Stem Cells. Prepublished on May 29, 2008, as DOI: 10.1634/stemcells.2008-0377.
71. Xu M, Bruno E, Chao J, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005;105:4508-4515.
72. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986-993.
73. Passamonti F, Rumi E. Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
74. Bock O, Neuse J, Hussein K, et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol. 2006;169: 471-481.
75. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta. J Immunol. 1994;153:2819-2830.
76. Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165:2271-2277.
77. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
78. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis: impact on disease phenotype. Eur J Haematol. 2007;79:508-515.
79. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-846.
80. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299-1307.
81. Bonnet D. Normal and leukaemic stem cells. Br J Haematol. 2005;130:469-479.
82. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005;105:1699-1705.
83. - hematopoietic stem cells recapitulates idiopathic myelofibrosis in the NOD/scid/IL2rgKO mice [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110:260.
84. Buschle M, Janssen JW. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2:658-660.
85. Kreipe H, Jaquet K, Feigner J, Parwaresch MR. Clonal analysis of agnogenic myeloid metaplasia. Leuk Lymphoma. 1992;8:459-464.
86. Oppliger Leibundgut E, Horn MP, et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica. 2006;91:1465-1472.
87. Pieri L, Guglielmelli P, Bogani C, et al. Mesenchymal stem cells from JAK2 (V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leuk Res. 2008;32:516-517.
88. Abbott A. Cancer: the root of the problem. Nature. 2006;442:742-743.
89. Xing Z, Ryan MA, Daria D, et al. Increased hematopoietic stem cell mobilization in aged mice. Blood. 2006;108:2190-2197.
90. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007; 110:4030-4036.
91. Schmidt A, Blanchet O, Dib M, et al. Bone changes in myelofibrosis with myeloid metaplasia: a histomorphometric and microcomputed tomographic study. Eur J Haematol. 2007;78:500-509.
92. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107: 4274-4281.
93. Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
94. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008:111:3931-3940.
95. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111:5109-5117.
96. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355-365.
97. Slayton WB, Li XM, Butler J, et al. The role of the donor in the repair of the marrow vascular niche following hematopoietic stem cell transplant. Stem Cells. 2007;25:2945-2955.
98. Thiele J, Varus E, Siebolts U, et al. Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation. Histol Histopathol. 2007;22:365-372.
99. Jasmin C. Leukemic stem cells and the curability of leukemias. Leuk Res. 1988;12:703-705.
100. Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol. 2008;15:121-126.
101. Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program. 2007;2007:346-354.
102. Catlin SN, Guttorp P, Abkowitz JL. The kinetics of clonal dominance in myeloproliferative disorders. Blood. 2005;106:2688-2692.
103. Wagner-Ballon O, Pisani DF, Gastinne T, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood. 2007;110: 345-353.
104. Shi J, Zhao Y, Ishii T, et al. Effects of chromatinmodifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007; 67:6417-6424.
105. Hasselbalch HC, Riley CH. The mevalonate pathway as a therapeutic target in the treatment of chronic myeloproliferative disorders. Current Drug Targets. 2007:8:247-256.
106. Kabelitz D, Wesch D, He W, Perspective of gammadelta T cells in tumor immunology. Cancer Res. 2007;67:5-8.
107. Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancertumor associated macrophages. Cancer Immunol Immunother. 2008;57:1451-1459.
108. Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007; 2007:371-375.